Arca
Skip to content
Tools
Tools

Takayasu arteritis

Drug research and approvals for takayasu arteritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 18 studies of takayasu arteritis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 2 open orphan designations naming it.

  • Recruiting worldwide: 18
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 18 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 6

Phase 2 4

How its trials ended

58 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong
  • Ongoing2136%
  • Completed, result not reported2034%
  • Status unknown1322%
  • Met its primary endpoint35%
  • Stopped: enrollment or feasibility12%

FDA orphan designations

Approved first, then open designations, newest first
Dec 5, 2025TocilizumabTreatment of Takayasu arteritisOddifact SASDesignated
Mar 13, 2025AdalimumabTreatment of Takayasu arteritisOddifact SASDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.